ONCY, CA6823108759

Oncolytics Biotech stock: Coherus deal backs anal-cancer study

Published on 11/19/2026 at 03:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Oncolytics Biotech stock gets a clinical supply deal with Coherus. A planned U.S. study will test pelareorep with LOQTORZI in anal cancer.

Clinical study plans take shape

  • Coherus will supply LOQTORZI for Oncolytics Biotech's planned anal-cancer study.
  • The trial is expected to begin in the first quarter of 2027 in the United States.
  • The study targets patients whose disease progressed after first-line chemotherapy and checkpoint inhibition.
ONCY, CA6823108759, Illustration mit AI erstellt.

On November 11, 2026, Oncolytics Biotech announced a clinical supply agreement with Coherus Oncology to evaluate pelareorep with LOQTORZI (toripalimab-tpzi) in squamous cell anal carcinoma. The company announcement published by GlobeNewswire said the planned study is expected to begin in the first quarter of 2027.

Coherus supplies the checkpoint inhibitor

Under the agreement, Coherus will provide LOQTORZI to Oncolytics. The study is expected to be conducted at a U.S. cancer center, which will be named when the trial starts, and Oncolytics expects to partner with the institution sponsoring the research.

The planned trial is aimed at patients whose squamous cell anal carcinoma has progressed after first-line chemotherapy and checkpoint inhibition. Oncolytics said there is no approved therapy for patients in this second-line setting. The agreement therefore extends the company's clinical development plan beyond its existing work with pelareorep and atezolizumab.

Development path remains clinical

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an investigational oncolytic virus immunotherapy. Its stated focus is regulatory approval for gastrointestinal cancers, including colorectal, anal and pancreatic cancer.

Business and development focus

Oncolytics Biotech develops pelareorep for gastrointestinal cancers and is pursuing late-stage clinical testing and regulatory approval. Its program covers colorectal, anal and pancreatic cancer indications with significant unmet medical needs. The company is headquartered in Canada and trades on Nasdaq under the ticker ONCY.

Oncolytics Biotech at a glance

  • Company: Oncolytics Biotech Inc.
  • ISIN: CA6823108759
  • Ticker: ONCY
  • Listing: Nasdaq
  • Focus: Pelareorep-based immunotherapy for gastrointestinal cancers

The Canadian market backdrop is covered in current S&P/TSX Composite reports.

More news and analyses on Oncolytics Biotech stock.

Disclaimer...
en | CA6823108759 | ONCY | boerse | 70533343 | bgmi